Prognostic prediction of oxidative stress related hematological biomarkers in locally advanced cervical cancer patients undergoing chemoradiotherapy

Biomarkers. 2024 Jul;29(5):255-264. doi: 10.1080/1354750X.2024.2358300. Epub 2024 May 30.

Abstract

Objective: This investigation aimed to develop and validate a novel oxidative stress score for prognostic prediction in locally advanced cervical cancer (LACC) patients receiving chemoradiotherapy.

Methods: A total of 301 LACC patients were enrolled and randomly divided into a training and a validation set. The association between oxidative stress parameters and prognosis was analyzed for oxidative stress score (OSS) establishment. A Cox regression model was conducted for overall survival (OS) and progression-free survival (PFS). A nomogram prediction model was developed using independent prognostic factors from the training set and validated in the validation set.

Results: A novel OSS was established with four oxidative stress parameters, including albumin, total bilirubin, blood urea nitrogen, and lactate dehydrogenase. Multivariate regression analysis identified OSS as an independent prognostic factor for OS (p = 0.001) and PFS (p < 0.001). A predictive nomogram based on the OSS was established and validated. The C-indexes of the nomogram in the training set were 0.772 for OS and 0.781 for PFS, while in the validation set the C-indexes were 0.642 for OS and 0.621 for PFS.

Conclusion: This study confirmed that preoperative OSS could serve as a useful independent prognostic factor in LACC patients who received CCRT.

Keywords: Oxidative stress score; biomarker; chemoradiotherapy; locally advanced cervical cancer; prognosis.

MeSH terms

  • Adult
  • Aged
  • Bilirubin / blood
  • Biomarkers, Tumor* / blood
  • Blood Urea Nitrogen
  • Chemoradiotherapy*
  • Female
  • Humans
  • L-Lactate Dehydrogenase / blood
  • Middle Aged
  • Nomograms*
  • Oxidative Stress*
  • Prognosis
  • Progression-Free Survival
  • Proportional Hazards Models
  • Uterine Cervical Neoplasms* / blood
  • Uterine Cervical Neoplasms* / mortality
  • Uterine Cervical Neoplasms* / pathology
  • Uterine Cervical Neoplasms* / therapy

Substances

  • Biomarkers, Tumor
  • Bilirubin
  • L-Lactate Dehydrogenase